S A Gregory1, L Trümper. 1. Rush University Medical Center, Section of Hematology and Stem Cell Transplantation, Chicago, IL 60612, USA. stephanie_gregory@rush.edu
Abstract
BACKGROUND: Higher chemotherapy dose intensity has been studied as a way of improving the clinical outcomes in various malignancies, including non-Hodgkin's lymphoma (NHL). METHODS: We reviewed clinical trials that have studied the relation between dose and response in cancer chemotherapy, the theory behind dose-intense chemotherapy, and the clinical results with dose-escalated and dose-dense therapy in aggressive NHL. RESULTS: Myeloablative high-dose chemotherapy with stem cell transplantation produces higher 5-year survival rates than standard salvage chemotherapy in relapsed aggressive lymphoma, but its role as initial therapy is not yet clear. Nonmyeloablative dose-escalated chemotherapy is feasible with granulocyte colony-stimulating factor (G-CSF) support, but this approach does not improve outcomes. Dose-dense (14-day) CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) with G-CSF support produces better results than 21-day CHOP in patients with previously untreated aggressive lymphoma, without additional toxicity. The addition of etoposide to dose-dense CHOP may provide further benefits in younger patients. The addition of rituximab to G-CSF-supported dose-dense CHOP is feasible. Preliminary data suggest the feasibility of dose-dense chemotherapy for NHL with the once-per-cycle G-CSF, pegfilgrastim. CONCLUSION: Dose-dense chemotherapy with G-CSF support produced better clinical outcomes in both younger and older patients. Phase 3 trials of dose-dense CHOP plus rituximab with CSF support are warranted.
BACKGROUND: Higher chemotherapy dose intensity has been studied as a way of improving the clinical outcomes in various malignancies, including non-Hodgkin's lymphoma (NHL). METHODS: We reviewed clinical trials that have studied the relation between dose and response in cancer chemotherapy, the theory behind dose-intense chemotherapy, and the clinical results with dose-escalated and dose-dense therapy in aggressive NHL. RESULTS: Myeloablative high-dose chemotherapy with stem cell transplantation produces higher 5-year survival rates than standard salvage chemotherapy in relapsed aggressive lymphoma, but its role as initial therapy is not yet clear. Nonmyeloablative dose-escalated chemotherapy is feasible with granulocyte colony-stimulating factor (G-CSF) support, but this approach does not improve outcomes. Dose-dense (14-day) CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) with G-CSF support produces better results than 21-day CHOP in patients with previously untreated aggressive lymphoma, without additional toxicity. The addition of etoposide to dose-dense CHOP may provide further benefits in younger patients. The addition of rituximab to G-CSF-supported dose-dense CHOP is feasible. Preliminary data suggest the feasibility of dose-dense chemotherapy for NHL with the once-per-cycle G-CSF, pegfilgrastim. CONCLUSION: Dose-dense chemotherapy with G-CSF support produced better clinical outcomes in both younger and older patients. Phase 3 trials of dose-dense CHOP plus rituximab with CSF support are warranted.
Authors: Kitsada Wudhikarn; Brian J Smith; Anna M Button; Thomas M Habermann; Carrie A Thompson; Lori J Rosenstein; Sergei I Syrbu; George J Weiner; James R Cerhan; Brian K Link Journal: Leuk Lymphoma Date: 2015-02-09
Authors: L Korashy; H El-Zawahry; S Abdou; D Shahin; F Sherif; W Farrag; O Abdel-Khalik; H Salem; A El-Sebaaie Journal: Clin Med Insights Oncol Date: 2012-11-26
Authors: Roberto Guariglia; Maria Carmen Martorelli; Rosa Lerose; Donatella Telesca; Maria Rita Milella; Pellegrino Musto Journal: Biologics Date: 2016-01-22
Authors: Nicola J Lawrence; Howard Chan; Guy Toner; Martin R Stockler; Andrew Martin; Sonia Yip; Nicole Wong; Annie Yeung; Danish Mazhar; Farzana Pashankar; Lindsay Frazier; Ray McDermott; Roderick Walker; Hsiang Tan; Ian D Davis; Peter Grimison Journal: BMC Cancer Date: 2018-08-29 Impact factor: 4.430
Authors: Manoj Menon; Anna Coghill; Innocent Mutyaba; Fred Okuku; Warren Phipps; John Harlan; Jackson Orem; Corey Casper Journal: PLoS One Date: 2018-02-01 Impact factor: 3.240